ALMS
Alumis Inc.Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-06 | Pangali Sanam |
Chief Legal Officer |
Sell↓
|
Common Stock
|
5,000 |
| 2026-07-06 | Pangali Sanam |
Chief Legal Officer |
Convert↑
|
Common Stock
|
5,000 |
| 2026-07-06 | Pangali Sanam |
Chief Legal Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares underlying this option vested on February 18, 2026, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
5,000 |
| 2026-06-30 | Machado Patrick |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date. |
Common Stock
|
3,553 |
| 2026-06-30 | Yao Zhengbin |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date. |
Common Stock
|
3,553 |
| 2026-06-30 | Srivastava Sapna |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date. |
Common Stock
|
3,553 |
| 2026-06-30 | AKKARAJU SRINIVAS |
Director, 10% Owner |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date. |
Common Stock
|
3,553 |
| 2026-06-30 | AKKARAJU SRINIVAS |
Director, 10% Owner |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date. |
Stock Option (Right to Buy)
|
15,528 |
| 2026-06-30 | Srivastava Sapna |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date. |
Stock Option (Right to Buy)
|
15,528 |
| 2026-06-30 | Yao Zhengbin |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date. |
Stock Option (Right to Buy)
|
15,528 |
| 2026-06-30 | TETRAULT LYNN A. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date. |
Stock Option (Right to Buy)
|
15,528 |
| 2026-06-30 | Machado Patrick |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date. |
Stock Option (Right to Buy)
|
15,528 |
| 2026-06-30 | TETRAULT LYNN A. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date. |
Common Stock
|
3,553 |
| 2026-05-22 | Drappa Jorn |
Chief Medical Officer |
Convert↑
|
Common Stock
|
15,535 |
| 2026-05-22 | Drappa Jorn |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares underlying this option vested on February 18, 2026, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
15,535 |
| 2026-05-22 | Drappa Jorn |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Includes 1,037 shares acquired on November 20, 2025 and 3,000 shares acquired on May 20, 2026 under the Issuer's 2024 Employee Stock Purchase Plan. |
Common Stock
|
11,317 |
| 2026-05-22 | Drappa Jorn |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares underlying this option vested on August 22, 2023, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
11,317 |
| 2026-04-01 | Tananbaum James B. |
Director |
Other↑
Filing footnotes — Common Stock (Indirect)
Represents shares received by Labs pursuant to pro rata distributions by Labs Affiliates, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act. The shares are held of record by Labs. Tananbaum, a manager of Labs, may be deemed to share voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs, except to the extent of his pecuniary interest in such securities. |
Common Stock
(I)
|
1,123,337 |
| 2026-04-01 | Foresite Labs, LLC |
10% Owner |
Other↓
Filing footnotes — Common Stock (Indirect)
Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Labs to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act. The shares are held of record by Labs. Tananbaum, a manager of Labs, may be deemed to share voting and dispositive power over such shares. |
Common Stock
(I)
|
1,123,337 |
| 2026-04-01 | Foresite Capital Management VI LLC |
10% Owner |
Other↑
Filing footnotes — Common Stock (Indirect)
Represents shares received by Labs pursuant to pro rata distributions by Labs Affiliates, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act. The shares are held of record by Labs. Tananbaum, a manager of Labs, may be deemed to share voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs, except to the extent of such person's pecuniary interest in such securities. |
Common Stock
(I)
|
1,123,337 |
| 2026-04-01 | Foresite Capital Management VI LLC |
10% Owner |
Other↓
Filing footnotes — Common Stock (Indirect)
Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Foresite Labs Affiliates 2021, LLC ("Labs Affiliates") to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The shares are held of record by Labs Affiliates. Foresite Labs, LLC ("Labs") is the managing member of Labs Affiliates and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), a manager of Labs, may be deemed to share voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs Affiliates, except to the extent of such person's pecuniary interest in such securities. |
Common Stock
(I)
|
1,176,470 |
| 2026-04-01 | Tananbaum James B. |
Director |
Other↓
Filing footnotes — Common Stock (Indirect)
Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Foresite Labs Affiliates 2021, LLC ("Labs Affiliates") to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The shares are held of record by Labs Affiliates. Foresite Labs, LLC ("Labs") is the managing member of Labs Affiliates and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), a manager of Labs, may be deemed to share voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs Affiliates, except to the extent of his pecuniary interest in such securities. |
Common Stock
(I)
|
1,176,470 |
| 2026-04-01 | Foresite Capital Management VI LLC |
10% Owner |
Other↓
Filing footnotes — Common Stock (Indirect)
Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Labs to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act. The shares are held of record by Labs. Tananbaum, a manager of Labs, may be deemed to share voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs, except to the extent of such person's pecuniary interest in such securities. |
Common Stock
(I)
|
1,123,337 |
| 2026-04-01 | Tananbaum James B. |
Director |
Other↑
Filing footnotes — Common Stock (Indirect)
Represents shares received by TFL Investment Holdings, LLC ("TFL") pursuant to pro rata distributions by Labs, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act. The shares are held of record by TFL. Tananbaum is the manager of TFL, and James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust, of which Tananbaum is a trustee, is the sole member of TFL. |
Common Stock
(I)
|
680,486 |
| 2026-04-01 | Foresite Labs, LLC |
10% Owner |
Other↑
Filing footnotes — Common Stock (Indirect)
Represents shares received by Labs pursuant to pro rata distributions by Labs Affiliates, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act. The shares are held of record by Labs. Tananbaum, a manager of Labs, may be deemed to share voting and dispositive power over such shares. |
Common Stock
(I)
|
1,123,337 |
| 2026-04-01 | Foresite Labs, LLC |
10% Owner |
Other↓
Filing footnotes — Common Stock (Indirect)
Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Foresite Labs Affiliates 2021, LLC ("Labs Affiliates") to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The shares are held of record by Labs Affiliates. Foresite Labs, LLC ("Labs") is the managing member of Labs Affiliates and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), a manager of Labs, may be deemed to share voting and dispositive power over such shares. |
Common Stock
(I)
|
1,176,470 |
| 2026-04-01 | Foresite Labs, LLC |
10% Owner |
Other↑
Filing footnotes — Common Stock (Indirect)
Represents shares received by TFL Investment Holdings, LLC ("TFL"). pursuant to pro rata distributions by Labs, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act. The shares are held of record by TFL. Tananbaum is the manager of TFL, and James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust, of which Tananbaum is a trustee, is the sole member of TFL. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any. |
Common Stock
(I)
|
680,486 |
| 2026-04-01 | Foresite Capital Management VI LLC |
10% Owner |
Other↑
Filing footnotes — Common Stock (Indirect)
Represents shares received by TFL Investment Holdings, LLC ("TFL"). pursuant to pro rata distributions by Labs, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act. The shares are held of record by TFL. Tananbaum is the manager of TFL, and James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust, of which Tananbaum is a trustee, is the sole member of TFL. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any. |
Common Stock
(I)
|
680,486 |
| 2026-04-01 | Tananbaum James B. |
Director |
Other↓
Filing footnotes — Common Stock (Indirect)
Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Labs to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act. The shares are held of record by Labs. Tananbaum, a manager of Labs, may be deemed to share voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs, except to the extent of his pecuniary interest in such securities. |
Common Stock
(I)
|
1,123,337 |
| 2026-01-26 | Bradley Mark Christopher |
Chief Development Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
190,225 |
| 2026-01-26 | Goldstein David M |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
216,675 |
| 2026-01-26 | Hardiman Roy C. |
Chief Business & Strategy Ofcr |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
190,875 |
| 2026-01-26 | Babler Martin |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
745,875 |
| 2026-01-26 | Drappa Jorn |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
221,450 |
| 2026-01-26 | Pangali Sanam |
Chief Legal Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
186,200 |
| 2026-01-26 | Schroer John R. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
202,225 |
| 2026-01-09 | AKKARAJU SRINIVAS |
Director, 10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
588,235 |
| 2026-01-08 | Foresite Labs, LLC |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
Common Stock
(I)
|
294,117 |
| 2026-01-08 | Foresite Capital Management VI LLC |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
Common Stock
(I)
|
294,117 |
| 2026-01-08 | Foresite Capital Management VI LLC |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
Common Stock
(I)
|
117,647 |
| 2026-01-08 | Tananbaum James B. |
Director |
Buy↑
Filing footnotes — Common Stock (Indirect)
The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
Common Stock
(I)
|
294,117 |
| 2026-01-08 | Tananbaum James B. |
Director |
Buy↑
Filing footnotes — Common Stock (Indirect)
The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
Common Stock
(I)
|
117,647 |
| 2026-01-08 | Foresite Labs, LLC |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
Common Stock
(I)
|
117,647 |
| 2025-12-05 | AKKARAJU SRINIVAS |
Director, 10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.48 to $9.4793 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
64,969 |
| 2025-12-05 | AKKARAJU SRINIVAS |
Director, 10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.48 to $10.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
70,028 |
| 2025-12-05 | AKKARAJU SRINIVAS |
Director, 10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.48 to $11.005 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
51,380 |
| 2025-12-04 | AKKARAJU SRINIVAS |
Director, 10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.65 to $8.41 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
66,027 |
| 2025-12-03 | AKKARAJU SRINIVAS |
Director, 10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.41 to $7.96 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
100,000 |
| 2025-12-02 | AKKARAJU SRINIVAS |
Director, 10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.41 to $7.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
96,000 |
| 2025-12-01 | AKKARAJU SRINIVAS |
Director, 10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.31 to $7.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
86,350 |